Key Points
The study, a phase-3 trial involving teenage girls and young women in South Africa and Uganda, showed that lenacapavir demonstrated zero (HIV) infections and 100 per cent efficacy, Gilead Sciences, Inc. said in a statement...
In the PURPOSE 1 trial, 5,338 participants, who were HIV-negative, to begin with, were divided into three groups - 2,134 receiving lenacapavir injections 26 weeks apart; 2,136 receiving the daily oral tablet Descovy (F/TAF); and 1,068 receiving the daily oral tablet Truvada (F/TDF)...
Researchers, including those from the Desmond Tutu HIV Centre, University of Cape Town, South Africa, observed a total of 55 infections - zero in the Lenacapavir group, 39 in the Desovy group and 16 in the Truvada group...
These stellar results show that twice-yearly lenacapavir for PrEP, if approved, could offer a highly effective, tolerable and discreet choice that could potentially improve PrEP uptake and persistence, helping us to reduce HIV in cisgender women globally, first author Linda-Gail Bekker, Director of the Desmond Tutu HIV Center at the University of Cape Town, South Africa, said in the statement...
Results of PURPOSE 2 trial, involving cisgender men, transgender men, transgender women and gender non-binary individuals in countries, including Latin American ones, South Africa and Thailand, are expected in late 2024 or early 2025, the statement said.. #England.
You might be interested in
Hope like never before — a drug that promises 100% protection from HIV
27, Jun, 24Lenacapavir, developed by Gilead Sciences, was tested as a pre-exposure prophylaxis in African women & is now being tested in other groups who are among the most vulnerable to HIV.
New HIV prevention drug Lenacapavir shows promise in clinical trial, offers total protection to young women
07, Jul, 24Lenacapavir injection proven highly effective in preventing HIV infections among young women compared to daily pills in clinical trial. | Health
Twice-yearly shot proves 100% effective in preventing HIV infection: Study
28, Jul, 24The findings of a new study highlight the potential of a drug called lenacapavir as a revolutionary HIV prevention method.
Indian pharma firms sign deal to produce, sell generic HIV drug lenacapavir
04, Oct, 24Indian pharmaceutical companies are set to produce generic versions of lenacapavir, an HIV prevention drug, under agreements with US-based Gilead Sciences to distribute it in 120 resource-limited countries.